24.06.2015 • News • Saudi • Sadara • investment

Sadara Wins Saudi “Strategic Rating”

The Saudi Arabian General Investment Authority (Sagia) has awarded Sadara, the joint venture between Saudi Aramco and Dow Chemical, the “Strategic”classification. With the award, the jv now enjoys the highest classification achievable under Sagia’s investment rankings.

The Saudi government’s investment authority said the classification is in recognition of Sadara’s commitment to enhancing the value of its investments in the petrochemical and chemical sectors of the country.

Sagia also praised the company for its success in attracting associated investments to the kingdom, which it said will provide significant employment opportunities for Saudi nationals and drive further development of the industry or associated industries.

Sadara is currently completing a mammoth €15 billion petrochemicals and plastics complex at Jubail Industrial City II in the eastern part of Saudi Arabia.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Top-Feature

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.